Nanogels that target blood clotting issues caused by sepsis
Loaded Fibrin-Specific Nanogels for Sepsis-Induced DIC
This study is testing a new way to help people with a serious condition called DIC, which can happen after infections, by using tiny gels that deliver medicine right to blood clots to help stop bleeding and break down harmful clots, aiming to improve treatment for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | North Carolina State University Raleigh NIH-funded |
| Lab location | 1 site (Raleigh, United States) |
| Project ID | NIH-10898131 on NIH RePORTER |
What this research studies
This research focuses on developing fibrin-specific nanogels that can deliver anticoagulant drugs directly to blood clots formed during disseminated intravascular coagulation (DIC), a serious condition often triggered by sepsis. The approach aims to enhance clot formation at bleeding sites while simultaneously dissolving harmful clots, addressing both prothrombotic and hemorrhagic symptoms. By using these nanogels, the researchers hope to improve treatment outcomes for patients suffering from DIC, which has a high mortality rate. The study will involve both animal models and human applications to evaluate the effectiveness of this innovative therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with sepsis who are experiencing symptoms of disseminated intravascular coagulation.
Not a fit: Patients with DIC not caused by sepsis or those with other underlying conditions that complicate treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce mortality rates and improve recovery for patients suffering from sepsis-induced DIC.
How similar studies have performed: Preliminary data from similar approaches using targeted drug delivery systems have shown promise, indicating potential for success in this novel application.
Where this research is happening
Raleigh, United States
- North Carolina State University Raleigh — Raleigh, United States (Active)
Researchers
- Principal investigator: Lutz, Halle — North Carolina State University Raleigh
- Study coordinator: Lutz, Halle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.